Subcutaneous administration of allergen vaccines

Allergens and Allergen Immunotherapy, Fourth Edition

Volumn , Issue , 2008, Pages 321-332

  Radtke, Michael ^a   Grammer, Leslie C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; VACCINE;

DESENSITIZATION; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; VACCINES;

EID: 58149476672     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (64)

1. Freeman J, Noon L. Further observation on the treatment of hayfever by hypodermic inoculations of pollen vaccine. Lancet 1911; 2: 814-817.
2. Reisman R., Tronolone M. Immunotherapy: a practical review and guide. Immunol Allergy Clin North Am 2000; 20(3): 469-478.
3. Cox L, Li J, Nelson H, et al. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120(3 suppl): S25-S85.
4. Grammer LC. Principles of immunologic management of allergic diseases due to extrinsic antigens. In: Grammer LC, Greenberger PA, eds. Patterson’s Allergic Diseases: Diagnosis and Management. Philadelphia: J. B. Lippincott, 2002: 183-194.
5. Norman PS. Allergic rhinitis. In: Austen KF, Frank MM, Atkinson JP, et al., eds. Samter’s Immunologic Diseases. Philadelphia: Lippincott Williams and Wilkins, 2001: 817-824.
6. Nelson HS. Immunotherapy for inhalant allergens. In: Adkinson NF, Yunginger JW, Busse WW, et al., eds. Allergy: Principles and Practice) Philadelphia, PA: C. V. Mosby, 2003: 1455-1473.
7. Portnoy J. Immunotherapy for inhalant allergies-guidelines for why, when and how to use this treatment. Postgrad Med 2001; 109: 89-106.
8. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007; 119(4): 872-880 [Epub February 9, 2007].
9. Bousquet J, Michel FB. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994; 94: 1-11.
10. Ewbank PA, Murray J, Sanders K, et al. A double-blind, placebo-controlled immunotherapy doseresponse study with standardized cat extract. J Allergy Clin Immunol 2003; 111(1): 155-161.
11. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994; 93: 556-566.
12. Horst M, Hejjaoui A, Horst V, et al. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460-472.
13. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mold allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986; 41: 507-519.
14. Esch RE, Bush RK. Aerobiology of outdoor allergens. In: Adkinson NF, Yunginger JW, Busse WW, et al., eds. Allergy: Principles and Practice. Philadelphia, PA: C. V. Mosby, 2003: 529-555.
15. Solomon, WR. Airborne pollen prevalence in the United States. In: Grammer LC, Greenberger PA, eds. Patterson’s Allergic Diseases. Philadelphia: Lippincott Williams & Wilkins, 2002: 131-144.
16. Sichere SH, Eggleston PA. Environmental allergens. In: Lieberman P, Anderson JA, eds. Allergic Diseases: Diagnosis and Treatment. Totowa, NJ: Humana Press, 2000: 41-51.
17. Baer H. Potency units for allergenic extracts in the USA. Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M 1987; 80: 167-168.
18. Lockey RF, Slater JE, Esch RE. Preparation and standardization of allergen extracts. In: Adkinson NF, Yunginger JW, Busse WW, et al., eds. Allergy: Principles and Practice. Philadelphia, PA: C. V. Mosby, 2003: 529-553.
19. Dreborg S. Precision of biologic standardization of allergenic preparations. Allergy 1992; 47: 291-294.
20. Helm RM, Gauerke MB, Baer H, et al. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol 1984; 73: 790-800.
21. Tippet J. Comprehensive care in the allergy/asthma office. Immunol Allergy Clin North Am 1999; 19(1): 129-148.
22. Bruun E. Controlled examination of the specificity of specific desensitization in asthma. Acta Allergol 1949; 2: 122-128.
23. Pence HL, Mitchell DQ, Greely RL, et al. Immunotherapy for mountain cedar pollinosis: a doubleblind controlled study. J Allergy Clin Immunol 1976; 58: 39-50.
24. Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during the pollen season. J Allergy Clin Immunol 1990; 86: 706-713.
25. Ortolani C, Pestorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double blind placebo controlled study in patients with grass pollen induced asthma and rhinitis. J Allergy Clin Immunol 1984; 73: 283-290.
26. Reid MJ, Moss RB, Hsu YP, et al. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986; 78: 590-600.
27. Norman PS, Winkenwerder WL, Lichtenstein LM. Immunotherapy of ragweed hayfever with antigen E: comparison with whole pollen extract and placebos. J Allergy 1968; 42: 93-108.
28. Van Meter TE, Adkinson NF, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and of the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980; 66: 500-513.
29. McHugh SM, Lavelle B, Kemeny DM, et al. A placebo controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with antigen specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86: 521-531.
30. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988; 78: 971-977.
31. Lent AM, Harbeck R, Strand M, et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006; 118(6): 1249-1256.
32. Nelson HS, Ikle D, Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J Allergy Clin Immunol 1996; 98: 382-388.
33. Bousquet J, Lockey R, Malling H. WHO panel members. Allergen immunotherapy: therapeutic vaccines for allergic diseases, a WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
34. Norman PS, Winkenwerder WL, Lichtenstein LM. Trials of alum-precipitated pollen extracts in the treatment of hayfever. J Allergy Clin Immunol 1972; 50: 31-44.
35. Van Metre TE, Marsh DG, Adkinson NF, et al. Immunotherapy decreases skin sensitivity to cat extract. J Allergy Clin Immunol 1989; 83: 888-899.
36. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. J Allergy Clin Immunol 1985; 76: 734-744.
37. Bousquet J, Guerin B, Dotte A, et al. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy 1985; 15: 179-193.
38. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. II Efficacy of a double blind, placebo controlled specific immunotherapy with standardized extracts J Allergy Clin Immunol 1991; 88: 43-53.
39. Hejjaoui JJ, Ferrando R, Dhivert H, et al. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol 1992; 89: 925-933.
40. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006; 97(2): 126-137.
41. Portnoy J, Bagstad K, Kanarek H, et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994; 73: 409-418.
42. Tankersley MS, Walker RL, Butler WK, et al. Safety and efficacy of an imported fire and rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002; 109: 556-562.
43. Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117(1): 134-140 [Epub December 2, 2005].
44. Casanovas M, Martin R, Jimenez C, et al. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol 2006; 139(2): 153-158 [Epub December 22, 2005].
45. Van Metre TE, Adkinson NF, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed hayfever. J Allergy Clin Immunol 1982; 69: 181-193.
46. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005; 116(1): 109-118.
47. Lockey RF, Benedict LM, Turkeltaub PC, et al. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79: 660-677.
48. Bernstein DI, Wanner M, Borish L, et al. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunolog. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990 to 2001. J Allergy Clin Immunol 2004; 113(6): 1129-1136.
49. Wohrl S, Gamper S, Hemmer W, et al. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol 2007; 144(2): 137-142.
50. Roy SR, Sigmon JR, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2007; 99: 82-86.
51. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004; 92(2): 225-227.
52. Tankersley MS, Butler KK, Butler WK, et al. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol 2000; 106(5): 840-843.
53. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475.
54. Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol 2007; 98(5): 416-426.
55. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1986; 76: 297-301.
56. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe hayfever uncontrolled by antiallergic drugs. Br Med J 1991; 302: 265-269.
57. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004; 4(6): 543-548.
58. Creticos PS, Schroeder JT, Hamilton RG, et al. Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355(14): 1445-1455.
59. Casanovas M, Martin R, Jimenez C, et al. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin Exp Allergy 2007; 37(3): 434-440.
60. Casanovas M, Fernandez-Caldas E, Alamar R, et al. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137(3): 211-218 [Epub Jun 9, 2005].
61. Garcia-Robaina JC, Sanchez I, de la Torre F, et al. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118(5): 1026-1032 [Epub September 18, 2006].
62. Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116(3): 608-613.
63. Bousquet J, Hejjaoui JA, Skassa-Brociek W, et al. Double blind placebo controlled immunotherapy with mixed grass pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass pollen extract. Allergy Clin Immunol 1987; 80: 591-598.
64. Grammer LC, Shaughnessy MA, Suszko IM, et al. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984; 73: 484-489.